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Take-home message: To gain insight into
the role of readmitted patients in the
nosocomial dynamics of antimicrobial-
resistant bacteria, we used colonization and
readmission data from the MOSAR
intensive care study, a study on intensive
care units in eight European countries, to
estimate the duration of colonization with
highly resistant Enterobacteriaceae,
methicillin resistant Staphylococcus aureus
(MRSA), and vancomycin-resistant
enterococci (VRE). We found that 50 % of
the patients had lost colonization when
readmitted 2 or more months after previous
ICU discharge.
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Abstract Purpose: Readmission
of patients colonized with antimicro-
bial-resistant bacteria (AMRB) is
important in the nosocomial dynam-
ics of AMRB. We assessed the
duration of colonization after dis-
charge from the intensive care unit




enterococci (VRE). Methods: Data
were obtained from a cluster-ran-
domized trial in 13 ICUs in 8
European countries (MOSAR-ICU
trial, 2008–2011). All patients were
screened on admission and twice
weekly for AMRB. All patients
colonized with HRE, MRSA, or VRE
and readmitted to the same ICU dur-
ing the study period were included in
the current analysis. Time between
discharge and readmission was cal-
culated, and the colonization status at
readmission was assessed. Because of
interval-censored data, a maximum
likelihood analysis was used to cal-
culate the survival function, taking
censoring into account. A nonpara-
metric two-sample test was used to
test for differences in the survival
curves. Results: The MOSAR-ICU
trial included 14,390 patients, and a
total of 64,997 cultures were taken
from 8,974 patients admitted for at
least 3 days. One hundred twenty-five
unique patients had 141 episodes with
AMRB colonization and at least 1
readmission. Thirty-two patients were
colonized with two or more AMRBs.
Median times until clearance were
4.8 months for all AMRB together,
1.4 months for HRE, \1 month for
MRSA, and 1.5 months for VRE.
There were no significant differences
between the survival curves. Conclu-
sion: Fifty percent of the patients
had lost colonization when readmitted
2 or more months after previous ICU
discharge.
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Introduction
The increasing prevalence of antimicrobial-resistant bac-
teria (AMRB) in health care facilities places a heavy load
on infection control policies. Readmission of patients
colonized with AMRB is an important factor in the nos-
ocomial dynamics of AMRB. It creates a ‘feedback loop’
where pathogens are reintroduced into the ward and can
colonize or infect new patients [1]. Yet, AMRB carriage
disappears after some time in most patients after dis-
charge. In many hospitals AMRB-positive patients are
‘flagged’ in patient systems in order to allow quick
identification at readmission [2–4]. Naturally, the feasi-
bility of this infection control measure would be enhanced
if patients could be safely ‘deflagged.’ However, little is
known about duration of colonization with AMRB after
hospital discharge.
Several studies have assessed the duration of carriage
of methicillin-resistant Staphylococcus aureus (MRSA) in
varying settings [2, 4–8], yielding large differences in
colonization duration. Results vary from 50 % clearance
in about 1 month [2] to a half-life of MRSA persistence of
40 months [4].
For highly resistant Enterobacteriaceae (HRE) and
vancomycin-resistant enterococci (VRE) estimates of
colonization duration are even scarcer, but also non-
consistent [9–18]. In Thailand [10], a median duration of
outpatient colonization with ESBL-producing bacteria of
98 days was observed, while a mean duration of carriage
of 9 months was reported among adopted children from
Mali [13]. For VRE, the reported median colonization
time was 7 weeks [15], and in another study VRE was
still recovered from 60 % of carriers of a particular out-
break strain, but only from 20 % of carriers of non-
epidemic strains after 6 months [14].
Knowledge about the time until clearance of AMRB is
of great importance for understanding nosocomial
dynamics and for predicting effects of interventions.
Colonization is a better indicator of bacterial dynamics
than infection, since colonization only leads to infection
in a small group but contributes significantly to the epi-
demiology of these bacteria [19]. Therefore, we assessed
the duration of colonization after discharge from the
intensive care unit (ICU) with HRE, MRSA, and VRE.
This work was presented in part at the 22nd ECCMID
2012, London, UK, 2 April 2012, abstract O126 [20].
Methods
Study design and study population
Data were obtained from a cluster-randomized trial in 13
ICUs in 8 European countries (MOSAR-ICU trial):
France (three ICUs), Greece (two ICUs), Italy, Latvia,
Luxembourg, Portugal (two ICUs), Slovenia (two ICUs),
and Spain. Data were prospectively collected from May
2008 until April 2011. The trial consisted of a 6-month
baseline period (phase 1), followed by implementation of
a hand hygiene improvement program and unit-wide
chlorhexidine body washing in months 7–26 (phase 2),
and surveillance screening for AMRB carriage at ICU
admission (followed by contact precautions for AMRB
carriers) with ICUs randomized to PCR-based or chro-
mogenic agar-based screening methods in months 13–26
(phase 3). During the whole study period, all patients
expected to stay for more than 2 days were screened on
admission and twice weekly for HRE, MRSA, and VRE.
More details can be found in the paper of Derde et al.
[21].
Written approval of the study protocol was obtained
from each institution’s review board or national ethics
committee. A waiver for informed consent was granted
for all participants since the study was considered to
involve no more than minimal risk of harm to patients
(ClinicalTrials.gov Identifier: NCT00976638).
All patients colonized with HRE, MRSA, or VRE in at
least one of the two last cultures during the first admission
and at least one readmission to the same ICU were
included in our study. HRE included Enterobacteriaceae
suspected to harbor extended-spectrum beta-lactamase
(ESBL): Escherichia coli (E. coli), Klebsiella, Entero-
bacter, Serratia, and Citrobacter (KESC), and Proteus,
Providencia, and Morganella (PPM) spp. The date of
discharge was taken as the start of the ‘at risk’ period for
clearance. This ‘at risk’ period for clearance was calcu-
lated as the time between discharge and readmission. At
readmission, we analyzed the first two available cultures
for every patient and labeled a patient as colonized if at
least one of these cultures was positive or decolonized if
both cultures were negative. We assumed admission was
non-informative with regard to colonization status. We
performed analyses for all bacteria together (looking at
colonization as the event of interest, regardless of the type
of bacteria the patients were colonized with) and for all
different bacterial types separately. When a patient was
colonized with more than one bacterial species in the
same admission, these were counted as separate coloni-
zation episodes. If a patient was admitted multiple times
while colonized, then each readmission was treated as a
new episode.
Microbiological tests
Swabs were obtained from the anterior nares (for detec-
tion of MRSA), the perineal area (for detection of HRE
and VRE), and wounds (if present, for detection of HRE,
MRSA, and VRE). Samples were frozen at -70/-80 C
for a maximum of 2 months before processing in phase 1
and 2, and samples were analyzed instantly in phase 3.
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The media used for detection of AMRB were Brilliance
ESBL 2 for detection of HRE, BBL CHROMagar MRSA
II for detection of MRSA, and BBL Enterococcosel Agar
with 8 lg/ml vancomycin for detection of VRE.
Statistical analyses
The time between discharge and readmission varied
between patients. Naturally, it was impossible to deter-
mine exact times until clearance for patients non-
colonized upon readmission, resulting in interval-cen-
sored data [22]. In Mathematica 7.0 (Wolfram Research,
Inc., Mathematica, Version 7.0, Champaign, IL), we used
a maximum likelihood analysis to calculate the survival
function, taking censoring into account. A more detailed
description of the method can be found in the paper of
Goggins and Finkelstein [22]. If a patient lost coloniza-
tion, then the day of readmission would not be taken as
the day of clearance (the last day of the interval, as would
happen using the more conventional Kaplan-Meier
method), but rather a day in the interval, calculated to be
most likely the day of clearance. Furthermore, with the
maximum likelihood analysis, sensitivity of the test could
be assessed. Graphs were constructed to visualize the
survival functions for the different bacteria. A nonpara-
metric two-sample test was used to test for significant
differences in the survival curves. This method was
developed by Andersen and Rønn [23], and a more
detailed description can be found in their paper.
In sensitivity analyses, we determined the effects of
detection bias by assuming that colonization remained
until discharge, and thus included all cases with at least
one positive culture any time during admission, and by
analyzing the first readmission culture instead of the first
two. Also, we analyzed the data excluding wound cultures
since they were taken infrequently and were dependent on
the presence of wounds. Furthermore, we investigated
different study phases separately (baseline versus inter-
vention period) to determine whether decolonization
therapy (chlorhexidine body washings), improved hand
hygiene, and surveillance screening with contact precau-
tions of identified carriers influenced colonization
duration. Finally, we checked whether there was a dif-
ference between patients who were readmitted from their
home and those coming from health care facilities
(including hospital wards and long-term care facilities).
Results
The MOSAR-ICU trial included 14,390 patients, and a
total of 64,997 cultures were taken from 8,974 patients
admitted for at least 3 days. There were 926 patients with
at least one readmission who had—in all—2,111
admissions during the study period. One hundred twenty-
five of these 926 patients were colonized with AMRB in
at least one of the last two cultures during their first
admission and had a subsequent readmission during the
study period and were included in the analysis (Fig. 1).
Details on patient characteristics can be found in Table 1.
When analyzing all AMRB together, 141 episodes of
colonization were recorded, including 32 episodes of
colonization with two or more organisms, 101 episodes of
HRE colonization (further divided into 34 for E. coli, 73
for the KESC, and 8 for the PPM group), 48 episodes of
colonization with MRSA, and 19 episodes of colonization
with VRE. The median times to clearance were around
1–2 months for all bacterial types (Table 2; Fig. 2). The
nonparametric two-sample test revealed no significant
differences between the survival curves of the different
bacteria.
For AMRB, the median time to clearance was
4.8 months, which was longer than for individual species.
This can be explained by the fact that, in this case, we
looked at colonization as the event of interest, regardless
of the type of bacteria with which the patients were col-
onized. When a patient was readmitted and colonized
with another type of bacterium than in his/her previous
admission, this was still counted as ‘colonized.’ In our
study, in 88 out of 98 cases in which a patient was still
colonized at readmission, this was with (at least) one of
the bacteria with which he/she was colonized in the pre-
vious admission. Ten cases were colonized with another
type of bacterium. The same applies to HRE: we regarded
a patient, colonized with HRE at discharge, as ‘still col-
onized’ at readmission if he/she was colonized with any
type of HRE. In 62 out of 65 cases in which a patient was
still colonized with an HRE at readmission, this was with
(at least) one of the bacteria with which he/she was col-
onized in the previous admission. For comparison, in the
Supplementary information data are analyzed using the
Kaplan-Meier method. Here, interval censoring is not
taken into account. For some bacteria, the results are
comparable (e.g., all AMRB together and all HRE toge-
ther), but for example for MRSA and VRE the time to
clearance is higher than the numbers derived using the
maximum likelihood method.
Sensitivity analyses
Including all cases with at least one positive culture any
time during admission instead of only looking at the last
two samples of the first admission period did not signif-
icantly influence the results (data not shown). Restricting
the analyses to the first culture of the readmission (instead
of the first two cultures) also did not change results (data
not shown). Furthermore, separate analyses of the dif-
ferent study phases or excluding wound cultures did not
significantly change results (data not shown). Finally,
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there were no significant differences between patients
being readmitted from home or from a health care facility.
Discussion
For all antimicrobial-resistant bacterial species, 50 % of
the patients had lost colonization when readmitted 2 or
more months after the previous ICU admission. Although
this study was performed on a selection of hospital
patients, i.e., patients admitted to ICUs, the results are of
critical importance since these patients are especially
prone to colonization and (subsequent) infection [19, 24].
From the figures, it seems that the percentage of patients
still colonized is stable for a period of time (especially for
all AMRB and HRE). One could hypothesize that there
are two distinct populations: the majority, which clears
colonization with AMRB quickly, and a minority (around
40 %) with longer persistence. More research is needed to
ascertain this.
The analysis of all AMRB can be seen as a special
case. Here, we did not assess the type(s) of bacterium a
patient was colonized with, but only colonization status
with any AMRB. Naturally, longer times to clearance
were found, since the type of bacterium at readmission is
not necessarily the same as the one at discharge from the
previous admission. This analysis shows that there might
be a risk group consisting of patients who are prone to
become colonized with any AMRB. What these specific
risk factors are was not addressed in this study, since it
was only applicable to ten patients.
Our study revealed shorter clearance times than pre-
viously reported, especially for MRSA [4–8], which may
have resulted from several methodological differences.
For example, for the calculation of the colonization
duration of MRSA, Scanvic et al. [5] only included
patients readmitted more than 3 months after discharge,
while we included all readmitted patients, regardless of
time since discharge. Although Larsson et al. [6] found a
median time to clearance of MRSA of 179 days
(5.9 months), they also demonstrated that 43 % of the
cases were colonized less than 2 months, which is more
similar to our results. In one of the first studies on colo-
nization duration of MRSA, Sanford et al. [4] estimated
the half-life of MRSA persistence in readmitted carriers to
Fig. 1 Flowchart of patient inclusion
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be 41 months. However, plasmid analysis and informa-
tion on phage types indicated that only a part of the cases
of persistent MRSA carriage had continued carriage of the
same strain and that the remainder represented acquisition
of a new strain. Mattner et al. [7] indicate that they tend to
overestimate the duration of colonization by regarding a
patient as ‘still colonized’ if the readmission swabs were
missed. This could partly explain the differences between
their median time to clearance (549 days) and the time
found in this study. However, our results are consistent
with the study of Robicsek et al. [2]. They also found that
50 % of the people lost colonization quickly (within
1 month). However, the colonization rate decreased
slowly thereafter.
Another reason for the differences with these studies is
that four of them used the Kaplan-Meier method to esti-
mate the median time to clearance [5–8]. As we pointed
out in the methods section, the exact time of clearance is
usually unknown, especially when readmission cultures
are used or when sampling is infrequent. As this will
result in interval-censored data, we used a maximum
likelihood analysis to calculate the survival function, with
censoring taken into account. This will yield more rapid
clearance times than a Kaplan-Meier estimate. Also, we
used a very specific patient population. Moreover, as our
results are based on the results of growth of cultures on
selective media and no genetic confirmation was used,
patients colonized upon readmission with a new strain
might be misclassified as still being colonized.
Our estimates on colonization duration with HRE were
lower than findings in another study [18]. This can be
explained by differences in study populations (ICU versus
whole hospital), the fact that only patients readmitted
after 3 months or more were included in the other study,
and the use of the Kaplan-Meier method. Our estimates of
duration of colonization are probably more accurate for
the first months, but since the other study covered a period
of 14 years, colonization and readmission after more than
1 or 2 years might have been captured better.
At readmission, we focussed on the first two cultures.
We required one or both of the readmission cultures to be
positive in order to label a patient (still) colonized. This
strategy was chosen to prevent false-negative results of
the first readmission culture, which may occur because of
sampling errors depending on the swabbing technique
used and the site swabbed [4, 25–28]. Perirectal swabs
were used in this study for detection of HRE and VRE,
but several publications suggest that the sensitivity of
rectal and perirectal swabs is comparable [25, 27]. Dif-
ferent practices in ICUs of all countries included could
induce different results. However, an extensive protocol
was provided to all study sites to standardize all aspects of
the main study [21]. Samples were not placed in enrich-
ment broth before plating, which might have influenced
the sensitivity of the test. Furthermore, the samples were
frozen and stored during baseline (although for a maxi-
mum of 2 months), which might have influenced the
results. Survival of gram-positive and -negative bacteria
during freezing and storage seems quite good [29, 30],
although the amount of bacteria recovered from frozen
suspensions may be reduced [31]. This could also have an
impact on the colonization times. If the sensitivity of the
tests were indeed reduced, shorter colonization times
would be found.
Table 1 Baseline
characteristics, n = 125 At first admission At readmission
Age in years, median (IQR) 63.0 (51.0–75.0) 64.0 (51.0–75.0)
Male, N (%) 78 (62.4 %) 78 (62.4 %)
Length of stay at ICU in days, median (IQR) 12.0 (6.0–22.5) 9.0 (5.0–18.0)
Location prior to ICU admission, N (%)
Home/private residence 29 (23.2 %) 14 (11.2 %)
Health care facility 88 (70.4 %) 103 (82.4 %)
Unknown/other 8 (6.4 %) 8 (6.4 %)
Had surgery in 12 months before ICU admission, N (%) 37 (30.8 %) 57 (47.1 %)
Time from discharge to readmission in days, median (IQR) n/a 11 (3.0–32.0)
Of all unique patients, data from their first admission and readmission in the study period were used.
Including subsequent admissions gave similar results (data not shown). Five cases had missing data on
some variables
IQR interquartile range
Table 2 Median times to clearance for antimicrobial-resistant
bacteria




All AMRB 141 4.8 (0.7–?)
HRE 101 1.4 (0.32–?)
E. coli 34 1.0 (0.03–7.6)
KESC 73 1.3 (0.08–?)
PPM 8 0.4 (0.02–?)
MRSA 48 0.4 (0.05–?)
VRE 19 1.5 (0.06–10.3)
568
In the intervention period of the MOSAR trial,
decolonization therapy (body washings with chlorhexi-
dine) was implemented. No mupirocin was used. Body
washing with chlorhexidine eradicates gram-positive
bacteria from the skin [32–37]. In the MOSAR trial,
patients were washed from the neck down. Since we
mainly used swabs taken from the nose for MRSA, one
could expect that chlorhexidine would not influence col-
onization at this site. However, chlorhexidine may
remove colonization or temporal contamination with
MRSA at other body sites. Hence, chlorhexidine may
lower the colonization pressure of gram-positive bacteria
and could be effective in prevention of transmission.
Little is known about the influence of chlorhexidine on
colonization with gram-negative bacteria [33]. However,
eradication seems unlikely given that the gut, the main
reservoir of gram-negative bacteria, is not targeted with
this decolonization therapy. To prevent a potential influ-
ence of chlorhexidine washings on colonization duration,
we only included patients with at least one positive cul-
ture in the last two cultures of their ‘first’ admission. In
this way, patients in whom carriage was eradicated were
excluded. Furthermore, when we analyzed the different
study phases separately, no significant differences in
colonization duration were found.
A limitation of this study is that the reasons for patient
readmissions were not known. We had no information on
whether these reasons were correlated with the coloni-
zation status of the patients. Therefore, we assumed
admission was non-informative with regard to coloniza-
tion status. We did have data on the ‘most specific reason
for ICU admission’ and there was no difference in the
prevalence of sepsis or in the type of sepsis (urinary tract
or other origin) in patients admitted to the ICU for the first
time in the study period or readmitted patients (data not
shown). Furthermore, there were no structured follow-up
cultures taken of discharged patients. Therefore, we do
not know exactly when colonization disappeared.
The prevalence and incidence of AMRB are different
per hospital and country, but this did not seem to influ-
ence the results. The maximal contribution of one hospital
to all cases was 18.7 % for AMRB, 21.8 % for HRE,
26.2 % for E. coli, 25.9 % for KESC, 62.5 % for PPM
(note: there were only eight cases), 21.0 % for MRSA,
and 29.4 % for VRE.
To our knowledge, this is the first study to assess the
duration of colonization of ICU patients with HRE. Fur-
ther studies with more readmitted colonized patients
could be of help to assess the time to clearance more
precisely.
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